目的 探討雙黃連口服液聯(lián)合磷酸奧司他韋顆粒治療小兒急性上呼吸道感染的臨床療效。方法 將2021年7月—2023年6月上海市奉賢區(qū)中心醫(yī)院收治的104例急性上呼吸道感染患兒作為研究對(duì)象，按照計(jì)算機(jī)隨機(jī)排列法分為對(duì)照組和治療組，每組52例。對(duì)照組開水沖服奧司他韋顆粒，體質(zhì)量≤15 kg患兒30 mg/次，體質(zhì)量＞15～23 kg患兒45 mg/次，體質(zhì)量＞23～40 kg患兒60 mg/次，體質(zhì)量＞40 kg患兒75 mg/次，2次/d。治療組對(duì)照組基礎(chǔ)上口服雙黃連口服液，3歲以下3 mL/次，3～5歲5 mL/次，5歲以上10 mL/次，3次/d。兩組患兒持續(xù)治療5 d。比較兩組的治療效果、癥狀消失時(shí)間、血清指標(biāo)。結(jié)果 治療組總有效率為96.15%，比對(duì)照組總有效率84.62%高，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，治療組退熱時(shí)間、止咳時(shí)間、痰消時(shí)間、流涕消失時(shí)間均短于比對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的血清中血清淀粉樣蛋白-A（SAA）、白細(xì)胞介素-18（IL-18）、白細(xì)胞介素-4（IL-4）、腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體（TRAIL）水平比治療前?。?i>P＜0.05）；治療組的血清SAA、IL-18、IL-4、TRAIL水平均比對(duì)照組低（P＜0.05）。結(jié)論 雙黃連口服液聯(lián)合磷酸奧司他韋顆粒治療小兒急性上呼吸道感染的療效確切，能夠改善臨床癥狀，減輕炎癥反應(yīng)。

Objective To investigate the clinical effect of Shuanghuanglian Oral Liquid combined with Oseltamivir Phosphate Granules in treatment of acute upper respiratory tract infection in children. Methods Children (104 cases) with acute upper respiratory tract infection in Shanghai Fengxian District Central Hospital from July 2021 to June 2023 were divided into control and treatment groups according to the computer random arrangement method, and each group had 52 cases. Children in the control group were po administered with Oseltamivir Phosphate Granules, with a body mass ≤ 15, >15 — 23, >23 — 40, and >40 kg with dosage of 30, 45, 60, and 75 mg/time, twice daily. Children in the treatment group were po administered with Shuanghuanglian Oral Liquid on the basis of the control group, 3 mL/time under 3 years old, 5 mL/time between 3— 5 years old, and 10 mL/time between 5 years old and above, three times daily. Children in two groups were treated for 5 d. The clinical efficacies, symptom disappearance time, and serum indicators in two groups were compared. Results The total effective rate of the treatment group was 96.15%, which was higher than 84.62% of the control group, and the difference was statistically significant (P < 0.05). Fever relief time, cough relief time, phlegm disappearance time, and runny nose disappearance time in the treatment group were shorter than those in the control group, and the difference was statistically significant (P < 0.05). After treatment, the serum levels of SAA, IL-18, IL-4, and TRAIL in two groups were lower than before treatment (P< 0.05), and the serum levels of SAA, IL-18, IL-4 and TRAIL in the treatment group were lower than those in the control group (P < 0.05). Conclusion Shuanghuanglian Oral Liquid combined with Oseltamivir Phosphate Granules is effective in the treatment of children with acute upper respiratory tract infection, which can improve the efficiency of symptom improvement, further reduce inflammation.

R974;R985

上海市科學(xué)技術(shù)發(fā)展基金項(xiàng)目（20170803）